Mankind Pharma has received approval for raising of funds by way of issuance of such number of equity shares having face value of Rs 1 each of the Company (Equity Shares) and / or other eligible securities or any combination thereof (hereinafter referred to as Securities), for an aggregate amount not exceeding Rs 7,500 crore or an equivalent amount thereof by way of issuance of equity / equity linked securities under qualified institutional placement (QIP) or through issuance of FCCBs, ADRs / GDRs / debt securities or through any other permissible mode in accordance with the applicable laws, subject to the receipt of the necessary approvals including the approval of the members of the Company and other regulatory / statutory approvals, as may be required.
The Board of Directors of the Company at its meeting held on May 15, 2024, has considered and approved the same.
Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |